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clinicaltrials. Alterationsincel proliferationanddifferentiation havebeenfoundinpreneopasticdiseasesandinnormal-
appearingcolorectal mucosaofpatientsat increased riskformalignancy. Several techniques areavailablefor measur-
ingthesealterations, andstandardizationandcomparisonofdifferentmethodsareunderwaytoassesstheutilityofvarious




cent years. This is partly because improvements in chemo-
therapy, radiotherapy, and surgery havenotsignificantlychanged
theprognosisofcolorectal cancer, andthismalignancy isstill one
oftheleading causes ofmorbidity andmortality inwestern coun-
tries (1). Epidemiologic studies and studies in rodent models
have indicated a possible chemopreventive role for various
natural substances and pharmacologic agents (2,3). However,
their effect on prevention ofhuman disease has generally not
beenclearlyestablished, andlargeclinicaltrials inhumans are
need for definitive results.
Oneofthemainproblems inplanning large, chemopreventive
interventions in humans is that the development ofmalignant
neoplasms is a slow, multistep process thatusually takes many
years. Moreover, theincidenceofcancerinthegeneralpopula-
tion is relatively low. Therefore, carrying out human chemo-
preventive intervention studies thatdecreasemorbidity and mor-
tality with neoplasia as anendpointhasbeen verytime comsum-
ing and costly. Insufficient subjects or short follow-upperiods
significantly decrease the powerofthesestudies, making itim-
possible to detect real but small protective effects of chemo-
preventive agents.
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Therefore, itappearstobeessentialtodevelopandvalidatein-
termediatebiomarkersofabnormalcellgrowthandmaturation
for use in chemopreventive intervention studies. These bio-
markersshouldbetheresultofactualeventsoccurringtheinitia-
tion and promotional phases oftumordevelopment in order to
be optimum candidates for modification by chemopreventive
agents. Intermediatebiomarkers withthesecharacteristics can
alsobetestedfortheirroleinidentifyingpopulationsatincreased
risk for cancer and in developing human screening programs
with reasonable cost-benefit ratios (4).
Biomarkers of Increased Suscepti-
bility toGastrointestinal Cancer
Intermediate biomarkers ofabnormal cell growth in human
subjects havebeendeveloped through several investigative ap-
proaches. These include the identification of individuals or
populationgroupsateitherincreasedoratlowriskforneoplasia
and the application of these groups to studies identifying
biomarkers that can be modulated by nutritional and chemo-
preventive interventions.
Ideal intermediate biomarkers ofabnormal cell growth that
canfunctioneffectively willeventuallyhavetobedemonstrated
tosatisfyusualcriteriaofconventionallaboratory tests(i.e., high
specificity, high sensitivity, goodpositiveandnegativepredic-
tivevalue). Moreover, inapopulationatincreasedriskforcancer
with abnormal expression of an intermediate biomarker, a
changeinexpressionofthebiomarkerinanormaldirectionby
achemopreventiveinterventionshouldreflectareducedriskof
neoplasia(5). Therefore, secondary eventsor "sideeffects" thatSCALMATIANDLIPKIN
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may accompany the evolution ofneoplasia are notapplicable as
biomarkers because they are not partofthe neoplastic process.
Thus, although anemia is a frequent finding patients with
atrophic gastritis atincreased risk forgastric cancer, reducing the
anemia does not reduce the cancer risk.
Moreover, intermediatebiomarkers should be reasonably easy
to measure in individuals and in population groups; the meas-
urements should be easy to standardize so thedataobtained from
different laboratories arecomparable. The measurement techni-
ques employed should also be sufficiently inexpensive and
reliable to be used in screening programs or in intervetion trials
involving many patients.
None of the biomarkers currently being studied have been
shown to fulfill all these criteria, but studies are now underway
to attempt to validate several intermediate biomarkers ofabnor-
mal cell proliferation, differentiation and gene expression; in
some of these studies chemopreventive agents have also been
given to subjects in high-risk populations to evaluate theireffects
on the biomarkers.
Biomarkers of Cell Proliferation
The incorporation of labeled DNA precursors by cells in S
phaseoftheproliferativecycle is aneffective and reliable way to
measure cell proliferation in renewing tissue (4). [3H]Deoxy-
thymidine (dThd) has been used fairly extensively in studies of
cell proliferation in human and rodent tissues, and it has been
possible to define normal numbers ofcells and spatial patterns
ofproliferating anddifferentiating cells in renewing mammalian
tissues and alterations in the cells and tissues ofpatients at in-
creased risk for neoplasia. With these measurements, patterns
ofcell proliferation have been shown to be modified in several
groups ofhuman subjects previously identified as being at in-
creased risk for gastrointestinal cancer and in rodent models
treated with chemical carcinogens. Bromodeoxyuridine (BrdU),
incorporated into the DNA ofcycling cells as is [3H]dThd, can
be detected with immunoperoxidase technique; the results ob-
tained with BrdU and (3H]dThd have generally beencomparable
after pulse injections.
Several diseases that affect individuals at increased risk for
colorectal cancer have been identified in which the size ofthe
proliferativecompartment has increased compared to low-risk
subjects (Table 1). Familialpolyposisisaninherited, autosomal
dominant disease characterized by a colon lined with adeno-
matouspolypsandthedevelopmentofcolorectalcanceratavery
early age; several extracolonic manifestations can also be
variably present in affected members of the kindreds. The
normal-appearing rectal mucosaofthe affected patients shows
apatternofcellproliferationthatclearlydiffersfromthatofnor-
malpeople. Theproliferativecompartmentofnormal colorec-
tal mucosaofindividuals at low risk forcolorectal cancer, and
of normal rodents, is located in the lower part ofthe colonic
crypts. The total labeling index (i.e., labeled cells versus total
cells)oflow-riskcontrolsandfamilialpolyposispatientsdoesnot
differ significantly, but the patients show a shift of the pro-




liferation in the crypts [see, for example, Deschner et al. (6,7)
and Lipkin et al. (8,9)].
Thepolypordysplasiacancersequenceisagenerallyaccepted
hypothesis related to thepathogenesisofcoloncancer (20,21),
and patterns ofcell proliferation in patients withadenomatous
polypshavebeenwidelystudied. Ithasbeenreportedthatanex-
pansionoftheproliferative compartmentispresentalongtheen-
tire colon in individuals at increased risk, no matter where the
lesion is (10,13,14). A correlation between size and degree of
dysplasia inadenomas anddegreeofalterationofcellprolifera-
tion alsohasbeen noted (12). Thetotallabelingindexofpatients
withpolypsorcancerhasbeenreportedtobesignificantly higher
than that ofnormal controls using [3H]dThd or BrdU in some
studies (8,11), andinotherscellproliferation intheuppercrypt
significantly increased, withcorresponding expansion in sizeof
the proliferative compartment (12,13,16).
Patients withprevious surgery forcolorectal cancerareknown
to be at increased risk forasecond malignancy; the mucosaof
remaining colonhas shown increasedoverall cellproliferation
andanincreased proliferativecompartment size inpatients with
recurrentpolyps compared tononrecurrent(15), suggesting an
association between increased cell proliferation and risk of
methachronous lesions. Chronic ulcerative colitis is a disease
characterizedby adefinedriskofcolorectal cancerthatisfurther
correlated tothe extentandduration ofthedisease. A shiftofthe
proliferative compartment towardsthe topofthecrypthas been
found inthenormal-appearing mucosaofpatientswithchronic
ulcerative colitis (17-19).
Several other methods have been used to measure cell pro-
liferation. Ki67 (22) and proliferating cell nuclear antigen
(PCNA) (23) aremarkers identifiedincycling cells, detectable
by immunohistochemistry, but their patterns ofexpression in
healthy mucosaandespecially indiseasehavenotyetbeenclear-
lydefined. Themetabolismofpolyamines andparticularly levels
ofakey enzyme, ornithinedecarboxylase (24), havebeen related
to cell proliferation, buttheirbiochemical determination inthe
tissue can only suggest total proliferative activity, and a minor
altered pattern may be undetectable ifit is notaccompanied by
an increase in the total labeling index. A similar problem can
Table 1. Expansion ofthe proliferative compartment ofepithelial cells in










Alterated mucin profiles Allen etal., 1988 (26)
Sugihara et al., 1987 (27)
Altered patterns ofcyto- Carboni et al., 1987 (28)
skeletal proteins Stallmach etal., 1990(29)
Blood-group antigens Kim et al., 1986 (30)
Itzkowitz et al., 1990 (31)
Yan et al., 1990(32)
Modified lectin-binding Rhodeset al., 1988 (33)
pattern Sams etal., 1990 (34)
arisefor measurementofthepercentageofcells inSphasedeter-
minedbycytofluorimetry (25); thisanalysisalso canonly give
an ideaaboutthetotal labeling index without any distinction of
cell proliferation in different parts ofthe crypt.
Biomarkers of Cell Differentiation
Thestudies listed inTable2 areonly aselectedlistwith afew
illustrationsofthetopicofcelldifferentiationbiomarkers. Cell
proliferation measurements are nowgainingincreasedcomplex-
ity (with new groupsofPCNAmoleculesassociatedwithcell cy-
cle functions), and cell differentiation biomarkers are similar-
ly becoming more complex. Multiple measurements are now
available todistinguish cycling cells fromquiescentproliferative
Table 3. Effect ofchemopreventive agents on biomarkers ofcell
proliferation and differentiation in humans.
Effect
Decreased hyperproliferation in
patients with familial colon cancer
(1250 mg daily for 3 months)
Decreased hyperproliferation in pa-
tients at increased risk (1250 mg
daily for2 months)
Decreased hyperproliferation inpa-
tients at increased risk (2000 mg
daily for 3 months)
Increased SBAbinding
Fiber Wheat bran (13.5 g fiber) decreased
rectal cell proliferation
Vitamins Ascorbic acid (3g daily for 18
months) decreased cell prolif-
eration in FAP patients
Betacarotine (20 mg daily for 2
years) contracted the zone ofpro-
liferation toward the crypt base in
patients with polyps
Vitamin A (30,000 U), vitamin C
(I g) and vitamin E (70 mg) (daily
for 6 months) reduced size ofpro-
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liferative compartment in flat rectal
mucosa in patients with adenomas
w-3 Fatty co-3 Fatty acids reduced size of Anti et al., 1991 (45)
acids proliferative compartment in flat
mucosa ofpatients with colorectal
adenomas
Abbreviations: SBA, soybeanagglutinin; FAP, fanmilial adenomatouspolyposis.
cells, degreesofcelldifferentiation, andlate-stageevents inthe
cell'slifecycle. Innormaladultcolorectal mucosa, which con-
tainscells atall stagesofdifferentiation, somecurrently studied
cell components include cytoskeletal elements, glycoproteins,




sialomucins in epithelial cells in chronic ulcerative colitis is
related todysplasiaandthat it can serve as abiomarkerofpro-
gression to malignancy (26). However, a lackofO-acetyl sub-
stituted sialic acid does not seem to be a marker of familial
adenomatous polyposis, a condition also associated with in-
creased cancer risk (27).
Amongcell componentsthatdevelopduringtheirnormal and
abnormal differentiation, cytokeratins and other intermediate
filaments become modified; it has been shown that their com-
positionsanddistributions varyindifferentcell typesduringdif-
ferentstagesofcelldifferentiationandindiseasestates. Thus, the
distribution of the brush-border-specific microvillar protein
villin, in human colonic mucosa detected by immunohisto-
chemistry, shows analtered pattern indysplastic and neoplastic
disease (28). Further, different proteins that bind basement
membrane glycoprotein laminin have been found in
preneoplastic compared to normal mucosa (29).
Carbohydratebloodgroup-relatedantigens arealsoexpressed
in colonic epithelial cells and show two kinds ofalterations in
preneoplastic andneoplastictissues (31). Thefirsttype involves
thesynthesisofnewepitopes notexpressedby normal mucosa,
usually accomplished by a process ofoligosaccharide elonga-
tion. Anexampleofthisistheexpressionofthetrifucosyl or ex-
tended LeYantigeninadenomasand cancercellsbutnotin nor-
mal mucosa(30). Thesecondkindofalterationobserved isthe
unmasking and subsequentexpression ofnormally cryptic an-
tigens following incompleteglycosylation (32). These antigens
are notexpressedby normal colonocytes, butthey areexpressed
inpremalignant colonictissue such as dysplastic adenomatous
polyps and chronic ulcerative colitis with dysplasia.
Lectin-binding ofcell surfacecarbohydrate residues becomes
modified with thedifferentiation ofnormal epithelial cells and
in stages ofdevelopment of precancerous diseases. Abnormal
patterns oflectinbindinghavebeendescribed in thecolorectal
mucosa of patients with inflammatory diseases or adenomas
(33,34).
FurtherAspects ofthe Molecular
Biology of Colon Cancer
Oncogenemutations, theoverexpression, deletion, and muta-
tion of tumor-suppressor genes, DNA hypomethylation, and
other genetic alterations have now been identified in preneo-
plasticandneoplastic lesions inthecolon. The familial adeno-
matouspolyposis genehasbeenlocated onchromosome5, and
a recently mapped point mutation and loss of p53 on
chromosome 17phasbeenfoundin somelesions. DCCandMCC
genes have been described, and myc also may be involved
(35,36). Among many reviews ofthis topic, several points are








certainty todetectmostorall individuals atrisk. Humancancers
appear to have a multistep evolution, and many environmental
factorsareinvolved. Attemptstomodulateorsuppressoncogene
expressionshavebegun andarelikelyto increase inthe future.
Therefore, itwould appearthat information onthe location,
structure, andfunctionofthegenesinvolvedincolorectal cancer
will be useful in selecting individuals for screening and for
chemopreventive interventions, and modifications that are in-
duced ingenestructure andexpressionmayprovetobeuseful in
assessing theefficacy ofinterventions. Following themultistep
conceptofcanceretiology, chemopreventionsmightinthefuture
beabletoinhibitinitiationorpromotioneventsincellsgenetical-
ly predisposed to cancer. The expressionofbiomarkers ofcell
differentiation andproliferation may similarly beuseful meas-
urements because they are theoretically modifiable.
Modulation ofCell Proliferation and
Differentiation Biomarkers by
Chemopreventive Interventions
A few selected examples of chemopreventive interventions
studiedinhumansaregiveninTable3. Fiber, calcium, vitamins,
and w-3 fatty acids are all constituents of human diets, and




consistent and reproducible results inmostanimal and human
studies, andcalcium supplementationinthedietinmoststudies
hasreducedexpansionsoftheproliferativecompartmentinpa-
tients with familial colon cancer predisposition and sporadic
adenomas (37-39). Calcium is unable to further decrease an
already low level ofproliferation (37). Inonestudycalciumalso
was showntochange soybeanagglutininlectinbinding, increas-
ing it toward apattern more typical ofwell-differentiated cells
(40). Resultsobtained withvitamins(42-44)andw-3fattyacids
(45) are also of interest, and measurements have begun in a
numberofstudies.
Conclusions
Intermediate biomarkers ofcell proliferation have generally
been reliableandquantifiable, presentinvariouspopulations at
risk, andmodifiablebychemopreventiveagents. However, dif-
ferencesdetectedareoftenverysmall, andcarefulevaluationsare
mandatory, including measurementsofsizeofproliferative com-
partments todetecteffects ofagents.
New measurements ofthestagesofcelldifferentiation arein-
creasing andarebeginningtobequantitated. Assessments ofcell
proliferation, differentiation, and gene structure andexpression
with intermediatebiomarkers arecurrently beingcarriedoutto
assesstheirutilityandtodetectmore subtlechanges inthecells
in chemoprevention studies.
This manuscript was presented at the Conference on Biomonitoring and
Susceptibility Markers inHumanCancer: Applications inMolecularEpidem-
iology and RiskAssessmentthatwasheldinKailua-Kona, Hawaii, 26October-I
November 1991.
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